Spotting-free nano-oscillator platform to measure how ligands bind to membrane proteins in cancer research
Official title: Spotting-free Nano-Oscillator Array for Quantification of Virion Displayed Membrane Protein Binding Kinetics
Funded at Biosensing Instrument, INC. · NIH-11321001 · Data updated 2026-11-12
A new high‑throughput, label-free method will measure how molecules bind to native cancer-related membrane proteins to help drug developers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biosensing Instrument, INC. NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project start | April 2, 2025 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $807,496 |
| NIH project number | 4R42GM157918-02 |
| Project ID | NIH-11321001 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with cancers where GPCRs or other transmembrane targets are relevant, or donors providing samples to help validate native receptor behavior.
✕Less likely to help
Patients not involved in cancer drug development or whose cancer targets are not transmembrane receptors may not directly benefit.
What this research studies
This project develops the Spotting-Free Nano-Oscillator Array (SFNOA) to quantify binding kinetics of ligands to transmembrane proteins in their native state. It uses virion-displayed receptors, aiming to improve sensitivity and throughput while avoiding loss of protein conformation. The work is geared toward accelerating cancer drug discovery by providing more accurate, rapid measurements of how potential therapies interact with targets on real cell surfaces.
Why it matters
Potential benefit: If successful, patients could benefit from faster development of effective cancer drugs with better-targeted action.
How similar studies have gone: Previous methods have struggled with native conformation and throughput; this project proposes a novel approach that could surpass current limitations.
Where this research is happening
-
Biosensing Instrument, INC.
Tempe, United States Active
Researchers
- Principal investigator: Ly, Nguyen — Biosensing Instrument, INC.
- Study coordinator: Ly, Nguyen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.